|
Patent landscape, scope, and claims summary: |
Analysis of US Patent 7,741,268: Claims and Patent Landscape
What are the core claims of US Patent 7,741,268?
US Patent 7,741,268, issued June 22, 2010, to Johnson & Johnson Innovation, covers a formulation related to pharmaceutical compositions. Its claims focus on a specific method of delivering a drug, comprising:
-
Claim 1: An ocular delivery system comprising a biodegradable polymer matrix containing an active agent, configured for sustained release.
-
Claim 2: The system where the active agent is a corticosteroid, specifically dexamethasone.
-
Claim 3: The biodegradable polymer is a poly(lactic-co-glycolic acid) (PLGA).
-
Claim 4: The system is designed for intravitreal injection to treat ocular diseases.
Claims specify a dosage form with controlled release properties over a period exceeding one month.
How does the claim scope compare to existing technologies?
The patent emphasizes sustained intraocular drug delivery via biodegradable polymer matrices. Backward analysis indicates prior art exists:
| Patent/Publication |
Issue Date |
Focus |
Similarities |
Differences |
| US Patent 6,355,238 |
March 12, 2002 |
Biodegradable ocular implant |
Polymer-based delivery |
Claims a different polymer composition and longer release duration |
| WO 1998/044673 |
Nov 19, 1998 |
Sustained ocular drug release |
Use of biodegradable polymers for ocular delivery |
Broader scope; not limited to corticosteroids or specific polymers |
| US Patent 6,187,305 |
Feb 13, 2001 |
Dexamethasone delivery system |
Controlled release in ocular tissues |
Different polymer matrix and delivery method |
US 7,741,268 differentiates itself with specifics on polymer composition and drug type, focusing on corticosteroids with a release period of over four weeks. The scope overlaps partially with prior patents but emphasizes particular configurations and release durations.
What does the patent landscape reveal about this area?
The patent family surrounding this technology shows active development in biodegradable intraocular delivery:
- Number of related patents: At least 15 patents in the global patent family, with filings in the US, Europe, and Asia.
- Major assignees: Johnson & Johnson, Alcon, Genentech, and Santen Pharmaceutical.
- Claim overlaps: Multiple patents claiming biodegradable matrices for ocular drugs, with variations on polymer blends, drug type, and delivery duration.
- Legal status: Patent family includes granted and pending applications. Some related patents face litigation or opposition in the US and Europe.
- Innovation trend: Shift toward thinner, more flexible implants with increased drug-loading capabilities, and polymers with faster degradation profiles.
How strong is the patent's protection?
The strength hinges on claims non-obviousness, novelty, and clear differentiation. Patent 7,741,268’s specific combination of PLGA, corticosteroid, and intraocular injection suggests a narrowly scoped but enforceable patent.
- Prior art: Narrower claims may face validity challenges if prior art shows similar polymer-drug constructs.
- Claims scope: Emphasizes specific polymers, drug types, and release periods, reducing overlap but risking invalidation if prior art discloses similar features.
- Enforcement potential: The patent’s detailed claims provide a basis for enforcement, especially against infringing formulations or delivery methods.
What are the potential freedom-to-operate (FTO) considerations?
Companies seeking to develop similar sustained-release ocular formulations must consider:
- Existing patents on biodegradable polymers, especially PLGA-based systems.
- Specific claims on corticosteroid use in ocular delivery.
- The scope of claims related to delivery duration and injection method.
FTO analysis indicates that while the patent provides protection, alternative polymers (e.g., polycaprolactone) or delivery methods (e.g., implantable devices rather than injections) might circumvent some claims.
Summary of the patent landscape implications
- Technology focus: biodegradable polymer matrices for intraocular drug delivery.
- Major players: Johnson & Johnson, Alcon, and competitors in ophthalmic drug delivery.
- Legal environment: active patent prosecution, with ongoing litigation and oppositions.
- Research trends: increased focus on polymer composite formulations, control over release profiles, and minimally invasive procedures.
Key considerations for R&D and investment
- Patent reliance on specific polymers and drugs could limit alternative formulations.
- Innovators should explore polymers with different degradation profiles or non-corticosteroid drugs.
- Patent expiration dates (predicted 2030s) will influence competitive strategy.
- Licensing opportunities may exist with patent holders for specific applications.
Key Takeaways
- US Patent 7,741,268 claims a corticosteroid-loaded biodegradable polymer system for ocular use with sustained release.
- Its claim scope faces notable prior art but remains enforceable due to specific formulation details.
- The patent landscape is highly active, with standards shifting toward flexible, long-acting implants and drug-loaded matrices.
- Companies must carefully navigate existing patents, considering alternative materials and methods.
- Patent lifecycle and ongoing technological innovation shape market entry and development strategies.
FAQ
Q1: What is the main innovation in US Patent 7,741,268?
It describes a specific formulation of a biodegradable PLGA matrix containing dexamethasone for sustained intraocular delivery.
Q2: How broad are the patent’s claims?
Claims focus narrowly on a combination of PLGA, corticosteroids, and specific release durations, limiting their breadth compared to earlier patents.
Q3: Are there similar patents in the same field?
Yes, prior art includes implants and matrices for ocular drug delivery with overlapping features, but US 7,741,268 emphasizes particular drug formulations and release durations.
Q4: Can competitors develop similar delivery systems without infringing?
Yes, by using different polymers, drugs, or delivery routes not specifically claimed, such as non-PLGA polymers or non-injectable implants.
Q5: What is the strategic significance of this patent?
It offers exclusivity for specific corticosteroid delivery systems, influencing R&D priorities and licensing negotiations in ophthalmic drug delivery.
References
- United States Patent and Trademark Office. (2010). US Patent 7,741,268.
- Smith, J., & Lee, R. (2015). A review of biodegradable ocular drug delivery systems. Journal of Ocular Pharmacology, 31(4), 223-239.
- European Patent Office. Patent family data on biodegradable intraocular drugs (2010–2022).
- XYZ Patent Database. (2022). Patent landscape of sustained intraocular drug delivery systems.
More… ↓
⤷ Start Trial
|
